We are committed to improving patient outcomes with innovative diagnostic solutions for acute and critical care that allow the diagnosis, outcome prediction, and monitoring of patients with acute medical conditions.
SphingoTec is a privately held company located in Hennigsdorf near Berlin, Germany. With a long history of biomarker discovery, development, and validation, we develop and market innovative IVD solutions for our novel and proprietary blood-based protein biomarkers.
Our aspiration is to effectively translate scientific advancements into routine clinical practice. We develop biomarkers addressing diagnostically underserved acute and critical care conditions such as sepsis, acute heart failure, and acute kidney injury, which are some of the biggest mortality drivers worldwide.